Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Senseonics Holdings Inc SENS

Healthcare Medical Devices
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The... see more

Recent & Breaking News (NYSEAM:SENS)

SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS

PR Newswire March 12, 2024

Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes

Business Wire March 8, 2024

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 29, 2024

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time

Business Wire February 15, 2024

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

PR Newswire February 12, 2024

PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care

Business Wire February 6, 2024

Senseonics Holdings, Inc. Announces Business Updates

Business Wire January 2, 2024

Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results

Business Wire November 9, 2023

Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference

Business Wire November 9, 2023

Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern Time

Business Wire October 30, 2023

Ascensia Diabetes Care and Senseonics Announce 'The CGM for Real Life' Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes

Business Wire October 9, 2023

Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Business Wire September 26, 2023

Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase

Business Wire September 14, 2023

Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital

Business Wire September 11, 2023

Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results

Business Wire August 10, 2023

Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time

Business Wire July 27, 2023

Senseonics Announces Equity Grants To Employees Under Inducement Plan

Business Wire July 5, 2023

New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

Business Wire June 26, 2023

Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes

Business Wire June 2, 2023

Senseonics to Participate in the Jefferies Healthcare Conference

Business Wire May 26, 2023